Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?
Sarcoidosis, an enigmatic disease with unknown etiology, is characterized by inflammation and the potential involvement of various organs, predominantly the lungs and intrathoracic lymph nodes. Non-caseating granulomas can resolve spontaneously in approximately 60% of cases within 2-3 years. However...
Saved in:
Main Authors: | Karol Bączek (Author), Wojciech Jerzy Piotrowski (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
by: Xing Lyu, et al.
Published: (2019) -
Antifibrotic Mechanism of Piceatannol in Bleomycin-Induced Pulmonary Fibrosis in Mice
by: Hanjing Sheng, et al.
Published: (2022) -
Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
by: Xiaohe Li, et al.
Published: (2019) -
Effectiveness and Safety of Antifibrotic Treatment in Pulmonary Fibrosis Associated with Rheumatoid Arthritis
by: Martyna Magdalena Martka, et al.
Published: (2024) -
Antifibrotic effect of Glycyrrhiza glabra on possible alternative treatment in oral submucous fibrosis
by: Pallavi Prakash Channe, et al.
Published: (2023)